As more covid-19 survivors are concerned with their immunity Dr. Chandra, CEO of Enzolytics sees a big revenue potential from IPF immune, an immunity booster, and recovery time reducer. In the Stock Day podcast, he highlighted several factors that will push the revenue to the next level.
In the next three months, Enzolytics is going to offer IPF Immune to Europe and Canada. These regions are also more inclined toward improving immunity after surviving a fatal pandemic. While testing it Enzolytics got positive results in combating CoronaVirus (SARS-CoV-2) strain 229e. This factual case is the strong data for the company to proudly introduce to those markets that are in sharp need of recovering human immunity.
Most certainly, this year ENZC shares may triple in the price unless insufficient marketing efforts lead to poor sales. By the way, throughout 10 days the stock has been attempting to pop over 10%.